Patents
Literature
2 results about "Vasospasm" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Vasospasm refers to a condition in which an arterial spasm leads to vasoconstriction. This can lead to tissue ischemia and tissue death (necrosis). Cerebral vasospasm may arise in the context of subarachnoid hemorrhage. Symptomatic vasospasm or delayed cerebral ischemia is a major contributor to post-operative stroke and death especially after aneurysmal subarachnoid hemorrhage. Vasospasm typically appears 4 to 10 days after subarachnoid hemorrhage.
Venous compression cuff
The utility model discloses a kind of venous hot compress sleeve, including the rectangular block of the sleeve main body made of skin-friendly material, sleeve main body is equipped with heating area, the left side of sleeve main body is equipped with first connecting belt, the right side of sleeve main body is equipped with second connecting belt, corresponding position of first connecting belt and second connecting belt is equipped with detachable connecting piece respectively, the position of first connecting belt close to sleeve main body is equipped with infusion leather strip connecting piece, the position of second connecting belt close to sleeve main body is equipped with elastic tightness area.The utility model can realize temperature controllable and heat preservation to a certain extent, improve hot compress operation convenience and security, not only can help patient expand venous vessel, promote drug absorption, also can relieve pain caused by vasospasm, reduce swelling or induration.
Owner:FUDAN UNIV SHANGHAI CANCER CENT
A perfusate for donation after cardiac death organ procurement and uses thereof
The application provides a kind of for heart death after organ acquisition perfusion fluid and its application, belong to medical technical field.The application is used for heart death after organ acquisition perfusion fluid, including the following components: thrombolytic drug, vasodilator, albumin, dexamethasone sodium phosphate, low molecular weight heparin sodium and lactated Ringer's solution.The organ acquisition perfusion fluid of the application can effectively remove the thrombus formed by coagulation system activation, reduce vasospasm caused by warm ischemic injury and tissue cell edema in the process of perfusion, which can effectively improve the quality and function of the acquired organ, increase the utilization rate of the organ, and has clinical transformation application prospect.
Owner:王彦峰 +1